Adalimumab Treatment of Life-Threatening Tuberculosis

被引：100

作者：

Wallis, Robert S. ^{[1
]}

van Vuuren, Cloete ^{[2
]}

Potgieter, Samantha ^{[2
]}

机构：

[1] Pfizer, New London, CT 06320 USA

[2] Univ Orange Free State, Dept Med, Bloemfontein, South Africa

来源：

CLINICAL INFECTIOUS DISEASES | 2009年 / 48卷 / 10期

关键词：

MYCOBACTERIUM-TUBERCULOSIS; PROCALCITONIN; THERAPY; ANTAGONISTS; PATIENT;

D O I：

10.1086/598504

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Most guidelines call for the discontinuation of treatment with tumor necrosis factor blockers in patients who develop tuberculosis. We report a case of life-threatening tuberculosis paradoxical reaction involving the lungs caused by withdrawal of the anti-tumor necrosis factor antibody adalimumab. Clinical improvement occurred only after resumption of adalimumab treatment.

引用

收藏

页码：1429 / 1432

页数：4

相关论文

共 23 条

[1] A patient with de novo tuberculosis during anti-tumor necrosis factor-α therapy illustrating diagnostic pitfalls and paradoxical response to treatment [J].

Arend, Sandra M. ;

Leyten, Eliane M. S. ;

Franken, Willeke P. J. ;

Huisman, Erik M. ;

van Dissel, Jaap T. .

CLINICAL INFECTIOUS DISEASES, 2007, 45 (11) :1470-1475

[2] Is it safe to readminister tumor necrosis factor α antagonists following tuberculosis flare? [J].

Aslanidis, Spyros ;

Pyrpasopoulou, Athina ;

Dourna, Stella ;

Petidis, Konstantinos .

ARTHRITIS AND RHEUMATISM, 2008, 58 (01) :327-328

[3] Flow cytometric analysis of procalcitonin expression in human monocytes and granulocytes [J].

Balog, A ;

Ocsovszki, I ;

Mándi, Y .

IMMUNOLOGY LETTERS, 2002, 84 (03) :199-203

[4]

Belknap R, 2005, INT J TUBERC LUNG D, V9, P1057

[5] Therapeutic Use of Infliximab in Tuberculosis to Control Severe Paradoxical Reaction of the Brain and Lymph Nodes [J].

Blackmore, Timothy K. ;

Manning, Laurens ;

Taylor, William J. ;

Wallis, Robert S. .

CLINICAL INFECTIOUS DISEASES, 2008, 47 (10) :E83-E85

[6] Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists [J].

Carmona, L ;

Gómez-Reino, JJ ;

Rodríguez-Valverde, V ;

Montero, D ;

Pascual-Gómez, E ;

Mola, EM ;

Carreño, L ;

Figueroa, T .

ARTHRITIS AND RHEUMATISM, 2005, 52 (06) :1766-1772

[7] The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis - Results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial [J].

Clair, EWS ;

Wagner, CL ;

Fasanmade, AA ;

Wang, B ;

Schaible, T ;

Kavanaugh, A ;

Keystone, EC .

ARTHRITIS AND RHEUMATISM, 2002, 46 (06) :1451-1459

[8] Time to detection of Mycobacterium tuberculosis in sputum culture correlates with outcome in patients receiving treatment for pulmonary tuberculosis [J].

Epstein, MD ;

Schluger, NW ;

Davidow, AL ;

Bonk, S ;

Rom, WN ;

Hanna, B .

CHEST, 1998, 113 (02) :379-386

[9]

Fonseca Joao Eurico, 2006, Acta Reumatol Port, V31, P247

[10] Dormancy phenotype displayed by extracellular Mycobacterium tuberculosis within artificial granulomas in mice [J].

Karakousis, PC ;

Yoshimatsu, T ;

Lamichhane, G ;

Woolwine, SC ;

Nuermberger, EL ;

Grosset, J ;

Bishai, WR .

JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 200 (05) :647-657